This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1buy
From Proteopedia
m (Protected "1buy" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:1buy.png|left|200px]] | ||
| - | |||
{{STRUCTURE_1buy| PDB=1buy | SCENE= }} | {{STRUCTURE_1buy| PDB=1buy | SCENE= }} | ||
| - | |||
===HUMAN ERYTHROPOIETIN, NMR MINIMIZED AVERAGE STRUCTURE=== | ===HUMAN ERYTHROPOIETIN, NMR MINIMIZED AVERAGE STRUCTURE=== | ||
| + | {{ABSTRACT_PUBMED_9783743}} | ||
| - | + | ==Disease== | |
| + | [[http://www.uniprot.org/uniprot/EPO_HUMAN EPO_HUMAN]] Genetic variation in EPO is associated with susceptbility to microvascular complications of diabetes type 2 (MVCD2) [MIM:[http://omim.org/entry/612623 612623]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. | ||
| + | |||
| + | ==Function== | ||
| + | [[http://www.uniprot.org/uniprot/EPO_HUMAN EPO_HUMAN]] Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. | ||
==About this Structure== | ==About this Structure== | ||
| Line 11: | Line 13: | ||
==Reference== | ==Reference== | ||
| - | <ref group="xtra">PMID:009783743</ref><references group="xtra"/> | + | <ref group="xtra">PMID:009783743</ref><references group="xtra"/><references/> |
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Aoki, K H.]] | [[Category: Aoki, K H.]] | ||
Revision as of 16:25, 24 March 2013
Contents |
HUMAN ERYTHROPOIETIN, NMR MINIMIZED AVERAGE STRUCTURE
Template:ABSTRACT PUBMED 9783743
Disease
[EPO_HUMAN] Genetic variation in EPO is associated with susceptbility to microvascular complications of diabetes type 2 (MVCD2) [MIM:612623]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Function
[EPO_HUMAN] Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.
About this Structure
1buy is a 1 chain structure with sequence from Homo sapiens. Full experimental information is available from OCA.
Reference
- Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol. 1998 Oct;5(10):861-6. PMID:9783743 doi:10.1038/2302
